CN105177141B - 在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 - Google Patents
在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 Download PDFInfo
- Publication number
- CN105177141B CN105177141B CN201510593883.6A CN201510593883A CN105177141B CN 105177141 B CN105177141 B CN 105177141B CN 201510593883 A CN201510593883 A CN 201510593883A CN 105177141 B CN105177141 B CN 105177141B
- Authority
- CN
- China
- Prior art keywords
- primer pair
- kit
- dna
- seq
- peripheral blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 21
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 18
- 102000000311 Cytosine Deaminase Human genes 0.000 title claims abstract description 14
- 108010080611 Cytosine Deaminase Proteins 0.000 title claims abstract description 14
- 230000014509 gene expression Effects 0.000 title claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 239000013615 primer Substances 0.000 claims description 30
- 230000003321 amplification Effects 0.000 claims description 29
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 29
- 238000003753 real-time PCR Methods 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 108091008146 restriction endonucleases Proteins 0.000 claims description 22
- 102000004533 Endonucleases Human genes 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 9
- 239000013641 positive control Substances 0.000 claims description 9
- 108010042407 Endonucleases Proteins 0.000 claims description 7
- 239000012295 chemical reaction liquid Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 108020001019 DNA Primers Proteins 0.000 claims description 3
- 239000003155 DNA primer Substances 0.000 claims description 3
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 43
- 238000001514 detection method Methods 0.000 abstract description 25
- 230000011987 methylation Effects 0.000 abstract description 7
- 238000007069 methylation reaction Methods 0.000 abstract description 7
- 101150032615 ung gene Proteins 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 38
- 230000029087 digestion Effects 0.000 description 23
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 20
- 239000012634 fragment Substances 0.000 description 17
- 230000035772 mutation Effects 0.000 description 16
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000009615 deamination Effects 0.000 description 6
- 238000006481 deamination reaction Methods 0.000 description 6
- 108010015866 endodeoxyribonuclease NheI Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002133 sample digestion Methods 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091023043 Alu Element Proteins 0.000 description 2
- 101150009927 Apobec3 gene Proteins 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510593883.6A CN105177141B (zh) | 2015-09-17 | 2015-09-17 | 在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510593883.6A CN105177141B (zh) | 2015-09-17 | 2015-09-17 | 在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105177141A CN105177141A (zh) | 2015-12-23 |
CN105177141B true CN105177141B (zh) | 2017-11-21 |
Family
ID=54899563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510593883.6A Active CN105177141B (zh) | 2015-09-17 | 2015-09-17 | 在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105177141B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107022614A (zh) * | 2017-04-21 | 2017-08-08 | 唐旌生物科技(上海)有限公司 | 一种检测基因突变的方法和试剂盒 |
CN108103163A (zh) * | 2018-01-17 | 2018-06-01 | 湖南大地同年生物科技有限公司 | 一种基因甲基化的检测方法 |
CN108676852B (zh) * | 2018-05-30 | 2021-08-27 | 朱运峰 | 在外周血游离dna中检测p53基因表观遗传学修饰差异的引物对组及试剂盒 |
CN108875314B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 一种基于表观遗传学修饰差异的靶基因的检测方法 |
CN113981046A (zh) * | 2021-11-05 | 2022-01-28 | 朱运峰 | 一种基于定量pcr技术dna甲基化检测方法及其试剂盒 |
CN113881752B (zh) * | 2021-12-07 | 2022-03-11 | 广东工业大学 | 一种用于检测核酸胞嘧啶脱氨酶apobec3b的试剂盒及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103710452A (zh) * | 2013-12-27 | 2014-04-09 | 朱运峰 | 检测外周血游离dna的试剂盒及寡核苷酸 |
-
2015
- 2015-09-17 CN CN201510593883.6A patent/CN105177141B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103710452A (zh) * | 2013-12-27 | 2014-04-09 | 朱运峰 | 检测外周血游离dna的试剂盒及寡核苷酸 |
Non-Patent Citations (6)
Title |
---|
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers;Steven A Roberts等;《NATURE GENETICS》;20130930;第45卷(第9期);第970-976页 * |
APOBEC3基因家族的生物学功能及其作用机制的初步研究;元小宁;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20150915(第9期);E072-7 * |
Comparison of the Differential Context-dependence of;Beale等;《JOURNAL OF MOLECULAR BIOLOGY》;20040326;第337卷(第3期);第685-596页 * |
Constitutive Expression of AID Leads to Tumorigenesis;Okazaki等;《JORNAL OF EXPERIMAENTAL MEDICINE》;20030505;第197卷(第9期);第1173-1181页 * |
Evidence for APOBEC3B mutagenesis in multiple;Michael B Burns等;《nature genetics》;20130714;第45卷(第9期);第977-983页 * |
尿嘧啶N糖基化酶的功能和表达调控;蒋欣彤等;《生命的化学》;20101231;第30卷(第3期);第444-448页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105177141A (zh) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105177141B (zh) | 在外周血游离dna中检测胞嘧啶脱氨酶及其相关分子基因表达的试剂盒及其引物对组 | |
Patnaik et al. | MicroRNA expression profiles of whole blood in lung adenocarcinoma | |
Hu et al. | Genetic variants of miRNA sequences and non–small cell lung cancer survival | |
US20230175066A1 (en) | Analysis/diagnosis method utilizing rna modification | |
EP2791359B1 (en) | Cancer diagnostics using non-coding transcripts | |
EP3452612B1 (en) | Detection of chromosome interaction relevant to breast cancer | |
Xia et al. | Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls | |
EP3704274B1 (en) | Genetic regulation of immunoresponse by chromosome interactions | |
CN103710452B (zh) | 检测外周血游离dna的试剂盒及寡核苷酸 | |
US20130084241A1 (en) | DEVELOPMENT OF miRNA DIAGNOSTICS TOOLS IN BLADDER CANCER | |
KR20230005927A (ko) | 종양 검출 시약 및 키트 | |
CN108796077B (zh) | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 | |
WO2010014975A2 (en) | Use of microrna signatures for assessing risk levels of neuroblastoma patients | |
US20230279498A1 (en) | Molecular analyses using long cell-free dna molecules for disease classification | |
CN110358835A (zh) | 生物标志物在胃癌检测、诊断中的应用 | |
CN107177676A (zh) | 长链非编码rna nonhsat113026用于肾癌诊断分子标志物的用途 | |
WO2023078276A1 (zh) | 一种基于定量pcr技术dna甲基化检测方法及其试剂盒 | |
Wong et al. | Integrated, longitudinal analysis of cell-free DNA in uveal melanoma | |
Xu et al. | Identification of Hub Genes as Biomarkers Correlated with the Proliferation and Prognosis in Lung Cancer: A Weighted Gene Co‐Expression Network Analysis | |
CN108676852B (zh) | 在外周血游离dna中检测p53基因表观遗传学修饰差异的引物对组及试剂盒 | |
CN114507738A (zh) | 甲基化位点、检测甲基化水平的产品的用途及试剂盒 | |
CN109609649B (zh) | 一种用于直肠腺癌诊疗的lncRNA | |
Han et al. | Regulation of pharmacogene expression by microRNA in the cancer genome atlas (TCGA) research network | |
Christophersen et al. | The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation | |
CN111961721B (zh) | 血浆sfmbt2基因甲基化在结直肠癌中转移预测及动态监测中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191205 Address after: 100094 130 / 132, floor 1, building 1, No. 538, yongfengtun, Haidian District, Beijing Patentee after: UPD Biotechnology (Beijing) Co., Ltd Address before: 100071, room 23, building 20, 1904 East Main Street, Beijing, Fengtai District Patentee before: Zhu Yunfeng |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151223 Assignee: Geppeard biomedical technology (Hebei) Co., Ltd Assignor: UPD Biotechnology (Beijing) Co.,Ltd. Contract record no.: X2020980004437 Denomination of invention: Kit and primer pairs for detection of gene expression of cytosine deaminase and its related molecules in peripheral blood free DNA Granted publication date: 20171121 License type: Exclusive License Record date: 20200728 |
|
EE01 | Entry into force of recordation of patent licensing contract |